These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15644988)

  • 21. Treatment of tardive dyskinesia with donepezil: a pilot study.
    Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
    J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
    Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
    World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of aripiprazole and tardive dyskinesia.
    Abbasian C; Power P
    J Psychopharmacol; 2009 Mar; 23(2):214-5. PubMed ID: 18515468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mania associated with initiation of ziprasidone.
    Nolan BP; Schulte JJ
    J Clin Psychiatry; 2003 Mar; 64(3):336. PubMed ID: 12716277
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
    Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
    Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 10-year follow-up study of tardive dyskinesia.
    Yassa R; Nair NP
    Acta Psychiatr Scand; 1992 Oct; 86(4):262-6. PubMed ID: 1360742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia in affective disorders.
    Kane JM
    J Clin Psychiatry; 1999; 60 Suppl 5():43-7; discussion 48-9. PubMed ID: 10192407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 37. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 38. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.
    Yuen O; Caligiuri MP; Williams R; Dickson RA
    Br J Psychiatry; 1996 Jun; 168(6):702-8. PubMed ID: 8773812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
    Bogers JPAM; Schulte PFJ; Broekman TG; Moleman P; de Haan L
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1024-1034. PubMed ID: 30025751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziprasidone induction of hypomania in depression?
    Davis R; Risch SC
    Am J Psychiatry; 2002 Apr; 159(4):673-4. PubMed ID: 11925314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.